Sao Tome and Principe vs Saint Vincent and the Grenadines: The number of people with susceptibility test result for rifampicin
Sao Tome and Principe
0
in 2021
Saint Vincent and the Grenadines
0
in 2021
Sao Tome and Principe rank
146th
Saint Vincent and the Grenadines rank
146th
The number of people with susceptibility test result for rifampicin over time
- Sao Tome and Principe
- Saint Vincent and the Grenadines
How they compare
Sao Tome and Principe currently reports 0 against 0 in Saint Vincent and the Grenadines, a difference of 0.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Sao Tome and Principe ahead.
Sao Tome and Principe ranks 146th and Saint Vincent and the Grenadines ranks 146th of 155 countries.
Across the 2 decades both report, Sao Tome and Principe averaged higher in 1 and Saint Vincent and the Grenadines in 1.
Head to head by decade
| Decade | Sao Tome and Principe | Saint Vincent and the Grenadines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 10.33 | 3.33 | 7 | Sao Tome and Principe |
| 2020s | 0.5 | 6.5 | 6 | Saint Vincent and the Grenadines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Sao Tome and Principe or Saint Vincent and the Grenadines?
- Sao Tome and Principe, at 0 against 0 in Saint Vincent and the Grenadines as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Sao Tome and Principe and Saint Vincent and the Grenadines?
- 0, with Sao Tome and Principe ahead.
- How many years of comparable data are there for Sao Tome and Principe and Saint Vincent and the Grenadines?
- 5 years are reported by both, from 2017 to 2021.
- How do Sao Tome and Principe and Saint Vincent and the Grenadines rank globally for the number of people with susceptibility test result for rifampicin?
- Sao Tome and Principe ranks 146th and Saint Vincent and the Grenadines ranks 146th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.